Literature DB >> 8292890

The progression associated antigen MUC18: a unique member of the immunoglobulin supergene family.

J P Johnson1, U Rothbächer, C Sers.   

Abstract

The cell surface glycoprotein MUC18 was originally identified as a progression associated antigen in melanoma. MUC18 is expressed most strongly on metastatic lesions and advanced primary tumours and is only rarely detected in benign lesions. cDNA cloning revealed MUC18 to be a novel member of the immunoglobulin superfamily with sequence similarity to a number of cell adhesion molecules. Cloning of both the human and mouse MUC18 genes indicate that their predicted protein structures are very similar with an overall amino acid identity of 75%. Like its human counterpart, murine MUC18 is also expressed by transformed melanocytes. Analysis of the promoter region of the human gene has provided evidence for regulatory elements found in smooth muscle specific genes and in both human and mouse: this is the normal site of MUC18 expression. The presence of putative binding sites for the transcriptional factors AP-1, AP-2 and CREB, suggest that MUC18 gene expression can also be modulated by external factors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8292890     DOI: 10.1097/00008390-199310000-00006

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  9 in total

Review 1.  The cellular basis of metastasis.

Authors:  P Ruiz; U Günthert
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 2.  The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis.

Authors:  J Nip; P Brodt
Journal:  Cancer Metastasis Rev       Date:  1995-09       Impact factor: 9.264

3.  Reduced GNG2 expression levels in mouse malignant melanomas and human melanoma cell lines.

Authors:  Ichiro Yajima; Mayuko Y Kumasaka; Yuji Naito; Toshikazu Yoshikawa; Hiro Takahashi; Yoko Funasaka; Tamio Suzuki; Masashi Kato
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

Review 4.  Lactobacillus adhesion to mucus.

Authors:  Maxwell L Van Tassell; Michael J Miller
Journal:  Nutrients       Date:  2011-05-20       Impact factor: 5.717

5.  CD146 as an adverse prognostic factor in uterine sarcoma.

Authors:  Yun Zhou; He Huang; Lin-Jing Yuan; Ying Xiong; Xin Huang; Jia-Xin Lin; Min Zheng
Journal:  Eur J Med Res       Date:  2015-08-21       Impact factor: 2.175

6.  Reduced CD146 expression promotes tumorigenesis and cancer stemness in colorectal cancer through activating Wnt/β-catenin signaling.

Authors:  Dan Liu; Lei Du; Dong Chen; Zhongde Ye; Hongxia Duan; Tao Tu; Jing Feng; Yili Yang; Quan Chen; Xiyun Yan
Journal:  Oncotarget       Date:  2016-06-28

7.  CD146, a novel target of CD44-signaling, suppresses breast tumor cell invasion.

Authors:  Allal Ouhtit; Mohammed E Abdraboh; Andrew D Hollenbach; Hatem Zayed; Madhwa H G Raj
Journal:  Cell Commun Signal       Date:  2017-11-09       Impact factor: 5.712

8.  CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer.

Authors:  Haofeng Zhang; Jun Zhang; Zhaoqing Wang; DI Lu; Jing Feng; Dongling Yang; Xiuqin Chen; Xiyun Yan
Journal:  Oncol Lett       Date:  2013-01-22       Impact factor: 2.967

Review 9.  CD146, from a melanoma cell adhesion molecule to a signaling receptor.

Authors:  Zhaoqing Wang; Qingji Xu; Nengwei Zhang; Xuemei Du; Guangzhong Xu; Xiyun Yan
Journal:  Signal Transduct Target Ther       Date:  2020-08-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.